News

Characterization and analysis of subvisible particles of biological origin can be challenging or give insufficient information. In this study Adeno associated virus (AAV) particles contaminated by host cell proteasomes are analysed with direct...

The Annual General Meeting of Vironova AB will be held on Monday 24 June 2019 at 15.00, at the Company's premises, at Gävleatan 22, in Stockholm - Sweden.

May 15-17, London, UK, EU

  Best practices from Vironova Biosafety. Vironova Biosafety specialize in viral clearance studies for biological drugs. These kinds of drug products based on live cells have an inherent risk for viral contamination that could cause serious harm or...

We are in the finals of the Third China Innovation & Entrepreneurship International Competition in Shenzhen.   Vironova won the "Swedish Overseas Division Competition" on March 26th in the "Third China Innovation & Entrepreneurship International...

Vironova are attending the conference in Boston to follow key industry trends, and join the conversation in the field of gene therapy. March 26-28, Boston, Massachusetts, USA

Meet Vironova at Bioprocessing Summit Europe 2019 Bioprocessing , March 19-21, Lisbon, Portugal. Vironova's Marketing Director Nina Forsberg will host and moderate a Round table, 19th of March at 16:45 on the topics and needs for analytical methods...

In both early-stage and late-stage development operations of viral vector-based therapies - such as gene therapies, vaccines, or oncolytic virotherapy - access to accurate analytical data is critical. Reduction of risk and quick decision making...

Download our new AAV gene therapy vectors application note Are you interested in characterization of AAV gene therapy vectors? Now you can download our new application note and find out how Vironova's MiniTEM:

meet us at ISBioTech 9th Spring meeting 2019 For more information on the prMarch 4-6, Norfolk,Virginia, USA